Absorption and Digestion Kinetics of Human Metabolites
Study Details
Study Description
Brief Summary
The purpose of this pilot study is to evaluate the effects oral supplementation with four human metabolites (spermidine, nicotinamide, palmitoylethanolamide (PEA), and oleoylethanolamide(OEA)) at varying doses on the circulating blood levels of these metabolites as well as their immediate effects on plasma functionality and postprandial inflammation. 5 young healthy subjects will participate in a four armed study consisting of a Placebo arm and a Low, Medium, and High Dose arm. Subjects will be given a standardized breakfast along with supplementation with either an escalating dose (Low: 1x, Medium: 2x, High: 3x) of a combination of spermidine, nicotinamide, PEA and OEA or a placebo control and a time course of their blood plasma will be collected after supplementation. Plasma samples will be assessed for their concentration of spermidine, nicotinamide, PEA, and OEA as well as their experimental and clinical functionalities including their anti-inflammatory, antioxidant, and cholesterol efflux abilities on primary human macrophage.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
N/A |
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Experimental: Low Dose The Low Dose arm provides subjects with supplementation with 5mg of spermidine (in the form of 5g of a 0.1% spermidine wheat germ extract), 500mg of nicotinamide, 400mg of palmitoylethanolamide, and 200mg of oleoylethanolamide. |
Dietary Supplement: Spermidine
Spermidine in the form of a 0.1% spermidine wheat germ extract
Other Names:
Dietary Supplement: Nicotinamide
Nicotinamide given as niacinamide
Other Names:
Dietary Supplement: PEA
Palmitoylethanolamide given at 98% purity
Other Names:
Dietary Supplement: OEA
Oleoylehtanolamide given at 90% purity
Other Names:
|
Experimental: Medium Dose The Medium Dose arm provides subjects with supplementation with 10mg of spermidine (in the form of 10g of a 0.1% spermidine wheat germ extract), 750mg of nicotinamide, 800mg of palmitoylethanolamide, and 400mg of oleoylethanolamide. |
Dietary Supplement: Spermidine
Spermidine in the form of a 0.1% spermidine wheat germ extract
Other Names:
Dietary Supplement: Nicotinamide
Nicotinamide given as niacinamide
Other Names:
Dietary Supplement: PEA
Palmitoylethanolamide given at 98% purity
Other Names:
Dietary Supplement: OEA
Oleoylehtanolamide given at 90% purity
Other Names:
|
Experimental: High Dose The Low Dose arm provides subjects with supplementation with 15mg of spermidine (in the form of 15g of a 0.1% spermidine wheat germ extract), 1000mg of nicotinamide, 1200mg of palmitoylethanolamide, and 600mg of oleoylethanolamide. |
Dietary Supplement: Spermidine
Spermidine in the form of a 0.1% spermidine wheat germ extract
Other Names:
Dietary Supplement: Nicotinamide
Nicotinamide given as niacinamide
Other Names:
Dietary Supplement: PEA
Palmitoylethanolamide given at 98% purity
Other Names:
Dietary Supplement: OEA
Oleoylehtanolamide given at 90% purity
Other Names:
|
Placebo Comparator: Placebo In this arm the participants are given supplementation with a placebo control consisting of 15g of wheat flour. |
Dietary Supplement: Wheat Flour
Wheat flour given as a placebo control
|
Outcome Measures
Primary Outcome Measures
- Circulating Plasma Levels of Metabolites [1, 2, and 4 hours after ingestion]
Quantitative plasma concentrations of spermidine, nicotinamide, pamitoylethanolamide, and oleoylethanolamide (in nmol/L).
Secondary Outcome Measures
- Anti-inflammatory capacity of plasma [1, 2, and 4 hours after ingestion]
Ex vivo assessment of the effects of subject plasma on the secretion of pro-inflammatory cytokine TNF-alpha (pg/mL) by primary human macrophage
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Age: 20-40 years old to constitute a young study population
-
BMI: 19-27 kg/m2 to constitute a normal/healthy weight population
-
Weight: 133lbs or more
-
Subjects must be willing and able to consume a standardized breakfast bar containing cashews and dates (Larabar).
-
Subjects must be willing to consume oral dietary supplement versions of spermidine, 1-methlynicotinamide, palmitoylethanolamide, and oleoylethanolamide.
-
Subjects must be willing and able to undergo blood draws at the UC Davis Ragle Nutrition Center at 0, 1, 2, and 4 hours after supplementation with spermidine, niacinamide, palmitoylethanolamide, and oleoylethanolamide.
Exclusion Criteria:
-
Smoker
-
Anemia
-
Documented chronic diseases including diabetes, thyroid disease, metabolic syndrome, cancer, autoimmune diseases, or previous cardiovascular events
-
Any inflammatory bowel disease including IBS, Crohn's Disease, Celiac Disease
-
Any allergy or sensitivity to wheat, gluten, or soy products
-
Consumption of >1 alcoholic drink/day
-
Current consumption of any probiotic, prebiotic, or dietary supplements
-
Extreme dietary or exercise patterns
-
Recent weight fluctuations (greater than 10% in the last six months)
-
Regular use of over-the-counter allergy or pain medications (>1/week)
-
Taking prescription lipid medications (e.g. statins) or other supplements known to alter lipoprotein metabolism such as isoflavones.
-
Use of any form of hormonal birth control including oral contraception pills, hormonal IUDs or rings, or hormonal birth control patches
-
Illness such as flu or cold of any kind within the last two weeks
-
Allergy to components of standardized breakfast bar (cashew/dates)
-
Changes to any of the above during the study period.
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | University of California Davis | Davis | California | United States | 95616 |
Sponsors and Collaborators
- University of California, Davis
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 1725738